EnteroMedics Extends Neuroblocking Technology R&D

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has extended its 2005 collaboration agreement with the Mayo Clinic for an additional two years. The collaboration will continue to focus on the research and development of vagal-blocking technology for the treatment of obesity and other gastrointestinal disorders. EnteroMedics will retain exclusive rights to obesity-related devices developed through this collaboration. Mayo Clinic has licensed technology to EnteroMedics and holds equity in the Company.

"Mayo Clinic is one of the leading authorities on the treatment of obesity," states President and CEO Mark B. Knudson, Ph.D., of EnteroMedics. "We value the long-term relationship that exists between EnteroMedics and Mayo. This extension allows us to continue collaborating with the Mayo Clinic as we look to advance the Maestro RC System into the pivotal phase of development."